The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 47 | — | 20.1x | Near average | |
Growth | 30 | — | 5.6% | Below average | |
Quality | 14 | -61.2% | 7.6% | Below average | |
Safety | 62 | 1.5x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Cullinan Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Cullinan Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The average price target for Cullinan stock saw a slight decline of 3.64% to reach $31, compared to $32.17 in previous readings, with the number of analysts holding steady at 7. This adjustment reflects a limited reduction in the ceiling of expectations despite the gap remaining significant between the current price ($13.84) and the lowest price target ($28), indicating that analysts maintain a fundamentally positive outlook despite the lowering of price targets.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.